Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675356 | 0.89 | MAPK1 (0.41) | KDRCCNA2CDK2MEN1KMT2A | |
| SCHEMBL1503877 | 0.87 | MEN1 (0.42) | KDRPDGFRBHSP90AA1HSP90B1CCNA2 | |
| SCHEMBL785706 | 0.82 | MAPT (0.63) | KDRPDGFRBHSP90AA1HSP90AB1ENPP2 | |
| SCHEMBL19553456 | 0.78 | FGFR4 (0.46) | CCNA2CDK2MEN1KMT2A | |
| SCHEMBL23501691 | 0.78 | HSP90AB1 (0.59) | KDRPDGFRBHSP90AB1MEN1KMT2A | |
| SCHEMBL28518471 | 0.78 | HSP90AA1 (0.47) | KDRPDGFRBHSP90AA1HSP90AB1ENPP2 | |
| SCHEMBL31340129 | 0.78 | HSP90AA1 (0.47) | KDRPDGFRBHSP90AA1HSP90AB1ENPP2 | |
| SCHEMBL14496907 | 0.78 | CYP2C9 (0.43) | KDRPDGFRBCCNA2CDK2 | |
| SCHEMBL21326642 | 0.78 | HSP90AA1 (0.59) | KDRPDGFRBHSP90AA1HSP90AB1MAPT | |
| SCHEMBL785547 | 0.78 | HSP90AA1 (0.59) | PDGFRBHSP90AA1HSP90AB1ENPP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | KDR 689/4885PDGFRB 136/4885HSP90AA1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.